IAPB, the peak body for the global eye care sector, welcomes a new patron to the eye health alliance: Roche.
The International Agency for the Prevention of Blindness (IAPB) is excited to announce that Roche has become a Patron, joining a select group of eye health leaders including Allergan, Bayer, Novartis and Standard Chartered Bank. Together, we are better placed to work to achieve universal eye health.
Today, more than 2.2 billion people are living with blindness or vision impairment. This is set to surge dramatically due to ageing and changes in lifestyle. It is estimated that by 2050, three times as many people will be blind as now, and half of the world will be living with short sightedness.
As part of the IAPB alliance, Roche will work with the agency to advocate for universal eye health, and support IAPB’s work in bringing together the eye health sector to achieve our common objectives.
Nick Parker, Head of Fundraising and Development, IAPB, said “we are delighted that Roche has joined IAPB. Together, we can work to promote eye health and ensure that it is integrated to overall health services at the country-level. The current COVID-19 crisis underscores how important this is, to increase efficiencies and ensure that a full package of health is available to people around the world.”
“Roche is excited to partner with the IAPB in our shared goal of promoting universal eye health,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This collaboration highlights our joint commitment to tackling the leading causes of visual impairment and blindness through pioneering therapies and impactful partnerships with the patient community.”
Roche and Genentech, a member of the Roche Group, have been instrumental in advancing the treatment paradigm and saving people’s eyesight from the leading causes of vision loss since 2006. Roche is working to bring forth innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, and strive to design the right therapies for the right patients.